San Diego, California, June 3, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial and viral metalloenzymes, ...
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 – Forge Therapeutics, Inc. (Forge) announced today that ...
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug 14, 2019 – Forge Therapeutics, Inc. (Forge), a ...
San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica ...
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. ...
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that it ...
-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, ...
2018 BIO International, ASM Microbe, and GRC Metals in Medicine San Diego, California, May 21, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology ...
San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David ...
-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, ...
